By Dominic Chopping
Novo Nordisk is buying Cardior Pharmaceuticals for up to $1.03 billion euros ($1.11 billion) as it moves to strengthen its pipeline of drugs to treat cardiovascular disease and expand into areas outside of its core diabetes and weight-loss market.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
03-25-24 0631ET